NBO Pharma Inc. — SEC Form D Filing

NBO Pharma Inc. filed an SEC Form D on January 22, 2026, reporting $7.64M raised in Pharmaceuticals.

Form D filing details

Filing
SEC Form D
Filing date
January 22, 2026
Amount reported
$7.64M
Round stage
Pre-Seed
Industry
Pharmaceuticals
Founded
2021
Website
https://nbopharma.com/

What the company does

Securities: Equity. Exemption: Rule 506(c). Incorporated: DELAWARE

Problem

Patients suffering from Idiopathic Intracranial Hypertension (IIH) currently lack approved drug treatments, leading to severe symptoms including potential vision loss.

Solution

NBO Pharma is developing an intranasal formulation of octreotide, an existing orphan drug, to treat IIH, aiming to provide an effective, less invasive, and better-tolerated treatment option.

Why now

There is a medical need for approved drug treatments for Idiopathic Intracranial Hypertension (IIH), and NBO Pharma is leveraging an existing drug with a novel delivery method to address this unmet need.

Verdict

Investors backed NBO Pharma on the promise of repurposing a known entity for an unmet medical need, a relatively de-risked path compared to *de novo* compound development. This cleared because the narrative centered on an orphan drug with a novel delivery mechanism, not because it introduced a completely new therapeutic. Their implicit bet was on successful clinical translation of the delivery method for an existing drug, and regulatory approval. Upside was limited by the niche market size of IIH and the typical competitive pressures in orphan drug development once a treatment shows promise.

Source: SEC EDGAR Form D filing